N/A
N=430
Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging
Endometrial Cancer · Cervical Cancer
Bottom Line
View on ClinicalTrials.gov: NCT01673022 ↗Enrolled (actual)
430
Serious AEs
5.1%
Results posted
Jul 2018
Primary outcome: Primary: Estimate the Sensitivity of the Sentinel Lymph Node — 418 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- IC Green (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Indiana University
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Estimate the Sensitivity of the Sentinel Lymph Node |
418 | — |
Summary
Description:
This is a multi-institutional study investigating the sensitivity and negative predictive value of sentinel lymph nodes mapped with robotic assisted near infrared imaging after cervical injection of indocyanine green (ICG) dye for women with stage I endometrial or cervical cancer at the time of their robotic surgical staging.
Patients will receive cervical injection of 1mg ICG after induction of anesthesia followed by sentinel lymph node mapping using robotic assisted fluorescence imaging. The sentinel lymph nodes identified will be removed and sent for ultraprocessing by pathology. The non-sentinel pelvic and para-aortic (if indicated) non-sentinel nodes will be removed and sent for routine pathologic processing according to standard of care for these surgical procedures. The pathologic results of the sentinel and non-sentinel nodes will be evaluated for sensitivity and negative predictive value in their ability to detect metastatic disease.
Eligibility Criteria
Inclusion Criteria
- Patients must be women 18 years and older who have biopsy proven endometrial or cervical carcinoma (of any histologic subtype).
- Surgical staging with the da Vinci Si robotic tool must be planned with a planned pelvic and, in the case of endometrial cancer, a para-aortic lymphadenectomy
- Patients must meet criteria for robotic surgical approach:
- Patients must have either a clinical stage I endometrial (of any histologic grade) or FIGO stage IA2 or IB1 (<4cm) cervical squamous, adenocarcinoma or adenosquamous carcinoma.
- Patients must be able to sign an informed consent in English language.
- Patients with known liver disease will require normal range liver function tests as determined by pre-operative labs drawn within 30 days of surgery.
Exclusion Criteria
- Patients who have iodide allergies
- Patients who have had previous retroperitoneal surgery
- Patients on whom pelvic+/- para-aortic lymphadenectomy is not planned as part of their surgical staging.
- Patients who have received previous treatment for their endometrial or cervical cancer (particularly hysterectomy or pelvic radiation).
- Patients who are pregnant.
- Patients with documented liver disease who have abnormalities of liver function tests.
Data sourced from ClinicalTrials.gov (NCT01673022). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.